M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma

Phase 1

Completed

Conditions: Melanoma
Eye Disease

Interventions: Procedure: Sentinel Lymph Node Mapping and Biopsy

First Posted Date: 2006-10-12

Last Posted Date: 2025-05-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 38

Registration Number: NCT00386906

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma

Not Applicable

Completed

Conditions: Non-Hodgkin's Lymphoma
Lymphoma

Interventions: Drug: Rituximab
Drug: Zevalin

First Posted Date: 2006-10-12

Last Posted Date: 2013-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT00387023

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients

Not Applicable

Completed

Conditions: Leukemia

Interventions: Drug: Imatinib Mesylate

First Posted Date: 2006-10-11

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00386373

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Psychosocial Impact of Cancer-Related Female Infertility

Completed

Conditions: Hodgkin's Disease
Cervical Cancer
Breast Cancer
Lymphoma

Interventions: Behavioral: Telephone Survey

First Posted Date: 2006-10-11

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 239

Registration Number: NCT00386217

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease

Phase 2

Completed

Conditions: Hodgkin's Disease

Interventions: Drug: Gemcitabine
Drug: Fludarabine
Drug: Melphalan
Drug: Antithymocyte Globulin
Procedure: Allogeneic Stem Cell Infusion
Drug: Tacrolimus
Drug: Filgrastim (G-CSF)
Drug: Methotrexate

First Posted Date: 2006-10-11

Last Posted Date: 2018-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT00385788

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Spousal Relationships and Pain in Metastatic Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Questionnaire
Behavioral: Interview

First Posted Date: 2006-10-11

Last Posted Date: 2015-07-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 548

Registration Number: NCT00386620

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cancer Patients' Medication Knowledge in the Emergency Center

Completed

Conditions: Advanced Cancer

Interventions: Behavioral: PMKT Questionnaire

First Posted Date: 2006-10-09

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 308

Registration Number: NCT00385476

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Risk Perception Among Quitting Smokers

Conditions: Smoking

Interventions: Drug: Nicotine Replacement Therapy
Behavioral: Questionnaire

First Posted Date: 2006-10-06

Last Posted Date: 2019-05-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 220

Registration Number: NCT00384696

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Endothelial Dysfunction As A Predictor Of Perioperative Outcome

Completed

Conditions: Endothelial Dysfunction

First Posted Date: 2006-10-06

Last Posted Date: 2019-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT00384683

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation

Phase 1

Completed

Conditions: Lymphoma
Leukemia
Transplantation, Stem Cell
Lymphoid Malignancies
Disorder Related to Transplantation

Interventions: Drug: GM-CSF
Drug: Rituximab
Biological: NK Cell Infusion

First Posted Date: 2006-10-04

Last Posted Date: 2019-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00383994

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy